紫杉醇联合卡铂同步放化疗在食管癌患者中的应用效果研究
Study on the effect of paclitaxel combined with carboplatin concurrent chemoradiotherapy in patients with esophageal cancer
张博亚 1张琳 1孔慧芳 1张羲茜 1魏梦霞1
作者信息
- 1. 郑州大学第一附属医院放疗科,郑州 450000
- 折叠
摘要
目的 研究食管癌患者应用紫杉醇联合卡铂同步放化疗的临床效果.方法 选取2020年1月-2022年1月郑州大学第一附属医院放疗科接受治疗的食管癌患者120例,随机分为对照组和实验组各60例,对照组应用卡铂注射液开展同步放化疗治疗,实验组在对照组基础上联合应用紫杉醇注射液治疗,治疗2个周期后,以疾病整体治疗效果、血清肿瘤标志物、1年内生存、复发情况以及不良反应情况作为观察指标,对比组间治疗效果.结果 治疗后实验组和对照组治疗有效率分别为75.00％、56.67％,实验组有效率更高,差异有统计学意义(P＜0.05);治疗前两组肿瘤标志物血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)水平比较(P＞0.05),治疗后均显著下降,且实验组CEA、CA19-9水平分别为(4.01±0.18)μg/L 及(35.88±0.65)μ/mL,均低于对照组,差异有统计学意义(P＜0.05);实验组1年内生存率95.00％较对照组高,而复发率5.00％则较对照组更低,差异有统计学意义(P＜0.05);实验组、对照组治疗期间不良反应发生率分别为21.67％、16.67％,差异无统计学意义(P＞0.05).结论 食管癌采用紫杉醇与卡铂联合开展同步放化疗疗效显著,可有效降低患者血清肿瘤标志物水平,降低复发风险,提升患者临床生存率,且未明显增加不良反应,整体疗效良好,值得临床推广应用.
Abstract
Objective To study the clinical effect of concurrent chemoradiotherapy with paclitaxel combined with carbo-platin in patients with esophageal cancer.Methlds A total of 120 patients with esophageal cancer who received treat-ment in the Radiotherapy Department of the First Affiliated Hospital of Zhengzhou University from January 2020 to Janu-ary 2022 were randomly divided into the control group and the study group,with 60 cases in each group.The control group received concurrent chemoradiotherapy with carboplatin injection,and the study group received combined treat-ment with paclitaxel injection on the basis of the control group.The overall treatment effect,serum tumor markers,1-year survival,recurrence and adverse reactions were used as observation indexes to compare the treatment effect between groups.Results After treatment,the effective rate of the study group and the control group were 75.00％and 56.67％,respectively,and the effective rate of the study group was higher,the difference was statistically significant(P＜0.05).The levels of carcinoembryonic antigen(CEA)and carbohydrate antigen 19-9(CA19-9)were signifi-cantly decreased in the two groups before treatment(P＞0.05),and the levels of CEA and CA19-9 in the study group were(4.01±0.18)μg/L and(35.88±0.65)μ/mL,respectively,which were lower than those of the control group.The difference was statistically significant(P＜0.05).The 1-year survival rate of the study group was 95.00％higher than that of the control group,and the recurrence rate of 5.00％was lower than that of the control group,with statistical significance(P＜0.05).The incidence of adverse reactions in the study group and the control group was 21.67％and 16.67％,respectively,with no statistical signifi-cance(P＞0.05).Conclusion Simultaneous chemoradiotherapy with paclitaxel combined with carboplatin for esopha-geal cancer has significant efficacy,which can effectively reduce the level of serum tumor markers in patients,reduce the risk of recurrence,and improve the clinical survival rate of patients without significantly increasing adverse reac-tions.The overall efficacy is good and worthy of clinical promotion and application.
关键词
食管癌/紫杉醇/卡铂/同步放化疗/治疗效果Key words
Esophageal cancer/Paclitaxel/Carboplatin/Simultaneous chemoradiotherapy/Therapeutic effect引用本文复制引用
基金项目
河南省医学科技攻关计划联合共建项目(LHGJ20210337)
出版年
2024
NETL
NSTL
万方数据